Investigation Report on China's Ustekinumab Market 2021-2025
|出版商||China Research and Intelligence||商品編碼||1006914|
|出版日期||內容資訊||英文 50 Pages
|中國的Ustekinumab市場分析(2021年∼2025年) Investigation Report on China's Ustekinumab Market 2021-2025|
|出版日期: 2021年05月21日||內容資訊: 英文 50 Pages||
Ustekinumab，是Janssen Pharmaceuticals 所開發的單株抗體醫藥品，主要用於乾癬，克隆氏症，潰瘍性大腸炎的治療。Janssen Pharmaceuticals的Ustekinumab "TELARA" ，2017年11月中國首次承認，2019年正式商品化銷售。至2020年，中國市場，Janssen-Cilag International NV 成為唯一的Ustekinumab的製藥企業。
Ustekinumab is a monoclonal antibody medication developed by Janssen Pharmaceuticals. It is mainly used to treat psoriasis, Crohn's disease, and ulcerative colitis. Janssen's Ustekinumab, STELARA was approved for its first indication in China in November 2017 and was officially commercialized and sold in 2019. By 2020, Janssen-Cilag International NV (BE) is the only manufacturer in the Chinese Ustekinumab market.
According to CRI's market research, after Ustekinumab entered the Chinese market, the sales increased from CNY0.6 million in 2019 to CNY 2.25 million in 2020. The annual growth rate is 274%
CRI analyzes that the sales of Ustekinumab will continue to increase in the next five years due to market expansion. After Ustekinumab was approved for its first indication in China in 2017, its second indication was approved in March 2020, which is used to treat moderate to severe active Crohn's disease. With the approval of the new indication, sales will increase accordingly. Besides, Ustekinumab had four approved indications globally, which means the number of approved indications has the potential to expand in China, so the sales will keep increasing. On the other hand, the relatively high price for Ustekinumab results in suboptimal sales in China. Since Ustekinumab has only been in the Chinese market for a short period, Janssen is not enthusiastic about the national medical insurance negotiation. However, with the emergence of domestic biosimilar drugs in the future, the price for Ustekinumab is expected to decrease and the market will be further expanded.